Antigen Loaded Particles for Tolerance Induction

用于耐受诱导的抗原负载颗粒

基本信息

  • 批准号:
    8305475
  • 负责人:
  • 金额:
    $ 50.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The undesired destruction of healthy cells by the immune system results in the loss of tissue function and complicates strategies to restore tissue function. The current standard therapy for autoimmune disease involves generalized immunosuppression, which is in most cases is not clinically efficacious and leads to numerous undesired side effects. Dr. Stephen Miller, (co-PI) pioneered an approach in which splenocytes were crosslinked with specific autoantigens, and their delivery to the spleen induced tolerance specifically to the autoantigen. The use of cellular carriers for tolerance induction in the clinical arena is challenging due to the considerable ex-vivo laboratory manipulation that is required, which is expensive, increases the number of donor cells needed and introduces further opportunity for technical error. Our long-term goal is to develop a particle-based platform that can be an off-the-shelf product for induction of tolerance to specific antigens to inhibit the specific undesired immune response while not altering the remaining elements of the immune response. In this proposal, we develop particles that target the spleen following intravenous delivery, and would subsequently be internalized by 'tolerogenic' antigen presenting cells to present the antigens without T cell activation thereby inducing tolerance rather than an immune response. Most strategies targeting the immune system focus on inducing a specific immune response (vaccines), whereas this system aims to do the opposite by inducing tolerance to specific antigens. We hypothesize that peptide-linked particles will be internalized by tolerogenic host splendid APCs which subsequently induce immune tolerance through the coordinate induction of T cell energy and activation of regulatory T cells that limit T cell responses. We have selected biocompatible and biodegradable materials whose physical properties can be controlled to influence their distribution, and can be modified with functional groups to promote internalization, target specific APC populations or receptors, and can release bioactive proteins to enhance the tolerogenic response. The following aims will be investigated: Specific Aim 1 will investigate particle design for splenic homing and antigen presentation in tolerance induction. Specific Aim 2 will investigate the innate cellular mechanisms that mediate interactions with antigen-linked particles that lead to tolerance. Specific Aim 3 will investigate mechanisms of particle-initiated inactivation of effectors T cell functions mediating tolerance induction including clonal deletion, energy/immune deviation, and Treg activation. Successful completion of these studies would identify particles that are novel, safe, efficient and clinically relevant tools to inhibit antigen-specific T- cells for therapy of autoimmune diseases. This innovative approach has far reaching implications for applications in which decreasing specific immune responses could be beneficial, such as the autoimmune diseases, rejection of transplanted cells, and allergies to food antigens or airborne particulates.
描述(申请人提供):免疫系统对健康细胞的不受欢迎的破坏导致组织功能的丧失,并使恢复组织功能的策略复杂化。目前对自身免疫性疾病的标准治疗包括全身性免疫抑制,在大多数情况下,这在临床上是无效的,并导致许多不受欢迎的副作用。史蒂芬·米勒(Stephen Miller)博士开创了一种方法,将脾细胞与特定的自身抗原交联,然后将其输送到脾中,诱导对自身抗原的特异性耐受。使用细胞载体在临床上诱导耐受是具有挑战性的,因为需要相当多的体外实验室操作,这是昂贵的,增加了所需的供体细胞的数量,并带来了进一步的技术错误的机会。我们的长期目标是开发一种基于颗粒的平台,它可以是一种现成的产品,用于诱导对特定抗原的耐受,以抑制特定的不受欢迎的免疫反应,同时不改变免疫反应的剩余成分。在这个提议中,我们开发了在静脉注射后以脾为靶点的颗粒,随后将被产生耐受性的抗原呈递细胞内化,在没有T细胞激活的情况下呈递抗原,从而诱导耐受性而不是免疫反应。大多数针对免疫系统的策略侧重于诱导特定的免疫反应(疫苗),而这个系统的目标是通过诱导对特定抗原的耐受性来做相反的事情。我们假设,多肽连接的颗粒将被耐受性宿主辉煌的APC内化,这些APC随后通过协调诱导T细胞能量和激活限制T细胞反应的调节性T细胞来诱导免疫耐受。我们选择了具有生物相容性和生物降解性的材料,这些材料的物理性质可以控制以影响它们的分布,并可以用官能团进行修饰以促进内化,靶向特定的APC群体或受体,并可以释放生物活性蛋白来增强耐受反应。将研究以下目标:特异性目标1将研究免疫耐受诱导中脾归巢和抗原提呈的颗粒设计。具体目标2将研究与导致耐受的抗原相关颗粒相互作用的固有细胞机制。具体目标3将研究粒子引发的T细胞功能失活的机制,包括克隆缺失、能量/免疫偏离和Treg激活。这些研究的成功完成将确定新的、安全、有效和临床相关的颗粒,以抑制自身免疫性疾病治疗中的抗原特异性T细胞。这种创新的方法对于降低特定免疫反应可能是有益的应用具有深远的影响,例如自身免疫性疾病、移植细胞的排斥反应以及对食物抗原或空气颗粒物的过敏。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEPHEN D MILLER其他文献

STEPHEN D MILLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEPHEN D MILLER', 18)}}的其他基金

Regulation of Neuromyelitis Optica via Tolerance Induced by PLG Nanoparticles Encapsulating Aquaporin 4 Epitopes
通过封装水通道蛋白 4 表位的 PLG 纳米颗粒诱导的耐受性调节视神经脊髓炎
  • 批准号:
    10088406
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
Allergen Loaded Nanoparticles for Food Allergy Tolerance
负载过敏原的纳米颗粒可提高食物过敏耐受性
  • 批准号:
    10093646
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
Allergen Loaded Nanoparticles for Food Allergy Tolerance
负载过敏原的纳米颗粒可提高食物过敏耐受性
  • 批准号:
    10264878
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
Allergen Loaded Nanoparticles for Food Allergy Tolerance
负载过敏原的纳米颗粒可提高食物过敏耐受性
  • 批准号:
    10466928
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
Regulation of CD4+ T cell-mediated Demyelination Following Oligo Ablation
寡核苷酸消融后 CD4 T 细胞介导的脱髓鞘的调节
  • 批准号:
    9382726
  • 财政年份:
    2017
  • 资助金额:
    $ 50.59万
  • 项目类别:
Regulation of CD4+ T cell-mediated Demyelination Following Oligo Ablation
寡核苷酸消融后 CD4 T 细胞介导的脱髓鞘的调节
  • 批准号:
    10198045
  • 财政年份:
    2017
  • 资助金额:
    $ 50.59万
  • 项目类别:
Antigen loaded particles for tolerance induction
用于耐受诱导的负载抗原的颗粒
  • 批准号:
    9056589
  • 财政年份:
    2011
  • 资助金额:
    $ 50.59万
  • 项目类别:
Antigen Loaded Particles for Tolerance Induction
用于耐受诱导的抗原负载颗粒
  • 批准号:
    8975040
  • 财政年份:
    2011
  • 资助金额:
    $ 50.59万
  • 项目类别:
Antigen Loaded Particles for Tolerance Induction
用于耐受诱导的抗原负载颗粒
  • 批准号:
    8473074
  • 财政年份:
    2011
  • 资助金额:
    $ 50.59万
  • 项目类别:
Antigen Loaded Particles for Tolerance Induction
用于耐受诱导的抗原负载颗粒
  • 批准号:
    8200645
  • 财政年份:
    2011
  • 资助金额:
    $ 50.59万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 50.59万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了